# Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes

> **NCT04567628** · — · COMPLETED · sponsor: **Takeda** · enrollment: 7873 (actual)

## Conditions studied

- Inflammatory Bowel Diseases
- Colitis, Ulcerative
- Crohn Disease

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT04567628
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-05
- **Primary completion:** 2021-09-22
- **Final completion:** 2021-09-22
- **Target enrollment:** 7873 (ACTUAL)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04567628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04567628, "Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04567628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*